This PDF file includes:

• Table S1. Primary myelofibrosis patient characteristics.
• Table S2. Clinical characteristics and genotype of reported cases of ruxolitinib withdrawal syndrome.
• Fig. S1. Graphical representation of experiments used in JAK inhibitor withdrawal studies in patient samples and TF1.8 cells.
• Fig. S2. Ruxolitinib washout triggers intracellular signaling.
• Fig. S3. Type I JAK2 inhibitor protects JAK2 from degradation and down-regulation.
• Fig. S4. Selective targeting of JAK1 kinase by itacitinib.
• Fig. S5. Type II JAK2 inhibitor CHZ868 blocks proliferation of cells expressing wild-type JAK2 and JAK2^V617F.
• Fig. S6. Type II inhibitor withdrawal does not trigger intracellular signaling.

Download PDF